Pablo Mora, MD, is the lead author of two new articles published in The Lancet. The articles report Phase 2 results for zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist being studied in adults with type 2 diabetes. Across cohorts, both once-weekly subcutaneous and once-daily oral formulations produced substantial improvements in glycemic control and … Read more
Tekton’s Principal Investigators are practicing physicians whose clinical experience and established patient relationships shape how we evaluate protocols and collaborate with Sponsors and CROs from the earliest stages of a study. On Tuesday, August 4, from noon to 1 p.m. ET, Jara McDonald, MD, FAAFP, DABOM, CPI, will present during the Society for Clinical Research … Read more
A new video featuring Pablo Mora, MD, FACE, MSc, CDCES, is now available in the Novo Nordisk ScienceHub. Dr. Mora provides an overview of the Phase 2 results for investigational zenagamtide (amycretin) in adults with type 2 diabetes. The findings were recently presented at the American Diabetes Association Scientific Sessions. In the 36-week study, once-weekly … Read more
Key Information New Carlisle, Ohio site will conduct MASH trials under Ashok Devatha, MD Embedded urgent care operation provides a high-traffic clinical access point, supported by Dr. Devatha’s primary care relationships Collaboration builds on July 2025 launch of the partnership in Yukon, Oklahoma Tekton Research, a multi-specialty clinical research site organization, is expanding its partnership … Read more
Site Selection Perspectives for Cardiometabolic and CNS Clinical Trials The Research Triangle is one of the most concentrated pharma and biotech ecosystems in the country. The companies headquartered there are running some of the most complex and consequential clinical trials in the industry today, particularly in cardiometabolic disease and neuroscience, two therapeutic areas where getting the site … Read more
Every treatment, therapy, and medical breakthrough begins with people. People willing to ask questions. People willing to care deeply. People willing to show up every day to move medicine forward. This Clinical Trials Day, we’re celebrating the people behind the progress at Tekton Research: the coordinators, investigators, site managers, nurses, recruiters, business development professionals, and … Read more
As CNS capabilities expand, Tekton adds seasoned leadership to accelerate growth and execution AUSTIN, TX – May 6, 2026 — Tekton Research, a leading multi-site clinical trial organization with 25 research sites across North America, today announced the appointment of Amit Vijapura, MD as a Central Nervous System (CNS) Key Opinion Leader (KOL), further strengthening … Read more
CNS (central nervous system) trials are some of the most complex–and most meaningful–studies in clinical research today. A recent Society for Clinical Research Sites (SCRS) SCRS Talks episode featuring Tekton’s Jeffrey Zucker and Brandon Lenfest explored the realities of conducting CNS trials—from patient identification to caregiver impact. In this article, we revisit the most compelling moments from that discussion and … Read more
As First Hub Opens, Tekton Adds New Principal Investigator, Dr. Arti Thangudu, and Expands Patient Access to Clinical Research AUSTIN, TX – April 8, 2026 — Tekton Research, a leading multi-site clinical trial organization with 25 research sites across North America, today announced the opening of its San Antonio research hub. A physician-led clinical research … Read more
Today is World Obesity Day – a moment to pause and reflect on one of the fastest-growing global health challenges of our time. More than 1 billion people worldwide are currently living with obesity. By 2035, that number is expected to rise significantly, with nearly half of the global population projected to be living with … Read more